- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease ; volume:14 ; number:1 ; day:15 ; month:1 ; year:2014 ; pages:1-8 ; date:12.2014
BMC neurology ; 14, Heft 1 (15.1.2014), 1-8, 12.2014
- Urheber
-
Burstein, Aaron H.
- Beteiligte Personen und Organisationen
-
Grimes, Imogene
Galasko, Douglas R.
Aisen, Paul S.
Sabbagh, Marwan
Mjalli, Adnan MM
SpringerLink (Online service)
- DOI
-
10.1186/1471-2377-14-12
- URN
-
urn:nbn:de:1111-2016030335217
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Burstein, Aaron H.
- Grimes, Imogene
- Galasko, Douglas R.
- Aisen, Paul S.
- Sabbagh, Marwan
- Mjalli, Adnan MM
- SpringerLink (Online service)
Ähnliche Objekte (12)
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Alzheimer’s Disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Alzheimer’s Disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease